BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

TREVENTIS Scientific Founder, Donald Weaver, MD, Named Sobey Chair in Alzheimer's Disease Research, His Third Endowed Chair


7/11/2012 11:17:02 AM

PHILADELPHIA, July 10, 2012 /PRNewswire/ -- TREVENTIS Corporation announced today that the Company's scientific founder, Donald F. Weaver, MD, PhD, was named as the Sobey Chair in Alzheimer's disease research at Dalhousie University in Halifax, Nova Scotia, Canada. This is the third endowed chair to be held by Dr. Weaver at Dalhousie. This chair has been established as the result of a $2 million donation to the Dalhousie Medical Research Foundation (DMRF) from the Sobey Foundation. It will fund the DMRF Irene MacDonald Sobey Endowed Chair in Curative Approaches to Alzheimer's Disease. The Sobey Foundation is funded by the Sobey family, who operate many diverse companies throughout Canada including chain grocery and drug stores.

Dr. Weaver, a pioneer in the field of computer-aided drug development, is on the trail of an Alzheimer cure. Dr. Weaver's group uses state-of-the-art computer-aided modeling to develop drugs to prevent and/or slow the progression of Alzheimer's disease. When certain proteins in the brain aggregate into clumps or tangles, that process is toxic to the brain, killing brain cells and leading to the symptoms of Alzheimer's dementia. Using computer models, Dr. Weaver is developing drugs that bind to multiple misfolding proteins in the brain, preventing them from aggregating and, thus, halting the brain damage associated with Alzheimer's disease.

The Sobey Chair in Alzheimer's will provide stable annual funding to assist Dr. Weaver and his team in their continued development of lead compounds as potential curative agents for the treatment of Alzheimer's disease. Dr. Weaver assigns these compounds for commercialization to TREVENTIS Corporation, a company that he helped found.

"We congratulate Don on this most prestigious appointment that serves to support his over- 20-year's work to discover a cure for dementias such as Alzheimer's," said Bill McIntosh, Chairman and CEO of TREVENTIS. "The Company is pleased to work toward the ultimate commercialization of his discoveries."

About TREVENTIS Corporation

TREVENTIS is headquartered in Southeastern Pennsylvania and has research operations in Halifax, Nova Scotia, Canada. The Company is focused on the discovery and early stage development of disease-modifying small molecule drugs for a variety of dementias including Alzheimer's. In addition to its therapeutic programs, TREVENTIS has a novel approach to the development of diagnostics for early diagnosis and monitoring of treatment effects in Alzheimer's disease.

Contact: L. William McIntosh

TREVENTIS, Chairman and CEO

Phone: 610-488-6081

wmcintosh.treventis@gmail.com

SOURCE TREVENTIS Corporation



Read at BioSpace.com

TREVENTIS
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES